Affinity DataIC50: 30nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women'S Hospital
US Patent
The Brigham and Women'S Hospital
US Patent
Affinity DataIC50: 44nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women'S Hospital
US Patent
The Brigham and Women'S Hospital
US Patent
Affinity DataIC50: 44nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women'S Hospital
US Patent
The Brigham and Women'S Hospital
US Patent
Affinity DataIC50: 190nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women'S Hospital
US Patent
The Brigham and Women'S Hospital
US Patent
Affinity DataIC50: 190nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women'S Hospital
US Patent
The Brigham and Women'S Hospital
US Patent
Affinity DataIC50: 4.18E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women'S Hospital
US Patent
The Brigham and Women'S Hospital
US Patent
Affinity DataIC50: 4.18E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Affinity DataIC50: 5.42E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Affinity DataIC50: 5.42E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Affinity DataIC50: 7.64E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Affinity DataIC50: 7.64E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair